Support adoption and use of Model Repository and Interoperability Framework
|Course||Exercise||Introduction||Type of data|
|Oncology (basic)||Tumor growth inhibition model||Estimation, Bayesian estimation and simulation using a preclinical tumour growth inhibition model (Simeoni et al. Cancer Res 2004).||Preclinical,disease (oncology), pharmacokinetics-pharmacodynamics (PKPD), Time-course data, simultation, estimation|
|CNS||An agonist-antagonist interaction model for prolactin.||An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatment. (Friberg et al. CPT, 2009)||Clinical, disease, time-course data, pharmacokinetics-pharmacodynamics (PKPD)|
|Cardiac Safety||Prediction of TQT study outcome based on early clinical data||Model-informed drug discovery and development online course to illustrate the principles of cardiac safety in drug discovery and development.
This includes consideration on preclinical, translational, clinical, regulatory expectation and modeling and simulation prospectives.
A hands-on exercise on translating preclinical QT interval (QTc) data from dogs to phase I clinical outcome in humans using pharmacokinetic–pharmacodynamic (PKPD) analysis for evaluation of Cardiac Safety risks using DDMoRe platform is available. (Parkinson et al. J Pharmacol Toxicol Methods 2013)
|Preclinical, clinical, time-course data, circadian variability|
|Infections||PKPD of antibiotics||Online course material on antibiotics and bacterial infections adapted from the Infectious disease course in model-informed drug development.
The material includes a brief background to the type of data typically used for PKPD-modelling, common PKPD-model structures with consideration of drug resistance as well as potential use in drug development.
The hands-on example illustrates the application of the DDMoRe platform for estimation and prediction using a PKPD-model developed from in vitro time-kill data
|In-vitro, pharmacodynamics (PD), time-course data, infectious disease|
|Oncology (Advanced)||Tumor growth inhibition model||Estimation, simulation and Optimal Design with a preclinical PKPD model of tumour growth under combination therapy (Rocchetti et al., Cancer Chemother Pharmacol 2013)||Preclinical, clinical, disease (oncology), pharmacokinetics-pharmacodynamics (PKPD), Time-course data, simultation, estimation, drug-drug interaction, optimal design|